IL6 and systemic lupus erythematosus: Hydroxychloroquine in an antimalarial agent, which has recently been shown to ameliorate SLE symptoms by inhibiting the production of IL-6, IL-17, and IL-22 possibly through reduction of the Th17 population [203].